484 related articles for article (PubMed ID: 26844233)
1. Mutanome Engineered RNA Immunotherapy: Towards Patient-Centered Tumor Vaccination.
Vormehr M; Schrörs B; Boegel S; Löwer M; Türeci Ö; Sahin U
J Immunol Res; 2015; 2015():595363. PubMed ID: 26844233
[TBL] [Abstract][Full Text] [Related]
2. Personalized cancer vaccines: Targeting the cancer mutanome.
Zhang X; Sharma PK; Peter Goedegebuure S; Gillanders WE
Vaccine; 2017 Feb; 35(7):1094-1100. PubMed ID: 27449681
[TBL] [Abstract][Full Text] [Related]
3. Cancer Neoantigens and Applications for Immunotherapy.
Desrichard A; Snyder A; Chan TA
Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495
[TBL] [Abstract][Full Text] [Related]
4. Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
Türeci Ö; Vormehr M; Diken M; Kreiter S; Huber C; Sahin U
Clin Cancer Res; 2016 Apr; 22(8):1885-96. PubMed ID: 27084742
[TBL] [Abstract][Full Text] [Related]
5. Neoantigen vaccine: an emerging tumor immunotherapy.
Peng M; Mo Y; Wang Y; Wu P; Zhang Y; Xiong F; Guo C; Wu X; Li Y; Li X; Li G; Xiong W; Zeng Z
Mol Cancer; 2019 Aug; 18(1):128. PubMed ID: 31443694
[TBL] [Abstract][Full Text] [Related]
6. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
Lancaster EM; Jablons D; Kratz JR
Genet Test Mol Biomarkers; 2020 Feb; 24(2):59-66. PubMed ID: 30907630
[TBL] [Abstract][Full Text] [Related]
7. Mutanome Engineered RNA Immunotherapy (MERIT).
Hum Gene Ther Clin Dev; 2015 Jun; 26(2):84-6. PubMed ID: 26086755
[No Abstract] [Full Text] [Related]
8. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
[TBL] [Abstract][Full Text] [Related]
9. Personalized vaccines for cancer immunotherapy.
Sahin U; Türeci Ö
Science; 2018 Mar; 359(6382):1355-1360. PubMed ID: 29567706
[TBL] [Abstract][Full Text] [Related]
10. Next generation approaches for tumor vaccination.
Patel A; Kaufman HL; Disis ML
Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672
[TBL] [Abstract][Full Text] [Related]
11. Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Kreiter S; Vormehr M; van de Roemer N; Diken M; Löwer M; Diekmann J; Boegel S; Schrörs B; Vascotto F; Castle JC; Tadmor AD; Schoenberger SP; Huber C; Türeci Ö; Sahin U
Nature; 2015 Apr; 520(7549):692-6. PubMed ID: 25901682
[TBL] [Abstract][Full Text] [Related]
12. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer.
Yin Q; Tang J; Zhu X
Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317
[TBL] [Abstract][Full Text] [Related]
13. The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.
Ward JP; Gubin MM; Schreiber RD
Adv Immunol; 2016; 130():25-74. PubMed ID: 26922999
[TBL] [Abstract][Full Text] [Related]
14. Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination.
Sun X; Zeng L; Huang Y
J Gene Med; 2019 Jul; 21(7):e3089. PubMed ID: 30958606
[TBL] [Abstract][Full Text] [Related]
15. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens.
Kiyotani K; Chan HT; Nakamura Y
Cancer Sci; 2018 Mar; 109(3):542-549. PubMed ID: 29288513
[TBL] [Abstract][Full Text] [Related]
16. Challenges and advances towards the rational design of mRNA vaccines.
Pollard C; De Koker S; Saelens X; Vanham G; Grooten J
Trends Mol Med; 2013 Dec; 19(12):705-13. PubMed ID: 24138818
[TBL] [Abstract][Full Text] [Related]
17. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
18. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
Gubin MM; Artyomov MN; Mardis ER; Schreiber RD
J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412
[TBL] [Abstract][Full Text] [Related]
19. The ReNAissanCe of mRNA-based cancer therapy.
Van Lint S; Renmans D; Broos K; Dewitte H; Lentacker I; Heirman C; Breckpot K; Thielemans K
Expert Rev Vaccines; 2015 Feb; 14(2):235-51. PubMed ID: 25263094
[TBL] [Abstract][Full Text] [Related]
20. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities.
Brennick CA; George MM; Corwin WL; Srivastava PK; Ebrahimi-Nik H
Immunotherapy; 2017 Mar; 9(4):361-371. PubMed ID: 28303769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
